Investing.com - EXACT Sciences (NASDAQ: EXAS) reported third quarter EPS of $-0.21, worse than the analyst estimate of $-0.20. Revenue for the quarter came in at $709M versus the consensus estimate of $716.8M.
Guidance
EXACT Sciences sees FY 2024 revenue of $2.73B-$2.75B versus the analyst consensus of $2.83B.
EXACT Sciences's stock price closed at $71.51. It is up 25.43% in the last 3 months and up 9.68% in the last 12 months.
EXACT Sciences saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See EXACT Sciences's stock price’s past reactions to earnings here.
According to InvestingPro, EXACT Sciences's Financial Health score is "good performance".
Check out EXACT Sciences's recent earnings performance, and EXACT Sciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar